AU2019388900B2 - Elacestrant in combination with abemaciclib in women with breast cancer - Google Patents

Elacestrant in combination with abemaciclib in women with breast cancer

Info

Publication number
AU2019388900B2
AU2019388900B2 AU2019388900A AU2019388900A AU2019388900B2 AU 2019388900 B2 AU2019388900 B2 AU 2019388900B2 AU 2019388900 A AU2019388900 A AU 2019388900A AU 2019388900 A AU2019388900 A AU 2019388900A AU 2019388900 B2 AU2019388900 B2 AU 2019388900B2
Authority
AU
Australia
Prior art keywords
dose
patient
day
abemaciclib
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019388900A
Other languages
English (en)
Other versions
AU2019388900A1 (en
Inventor
Nina K. ARAGAM
Charles Morris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Radius Pharmaceuticals Inc
Original Assignee
Radius Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Pharmaceuticals Inc filed Critical Radius Pharmaceuticals Inc
Publication of AU2019388900A1 publication Critical patent/AU2019388900A1/en
Application granted granted Critical
Publication of AU2019388900B2 publication Critical patent/AU2019388900B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2019388900A 2018-11-30 2019-11-26 Elacestrant in combination with abemaciclib in women with breast cancer Active AU2019388900B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862773960P 2018-11-30 2018-11-30
US62/773,960 2018-11-30
PCT/US2019/063239 WO2020112765A1 (en) 2018-11-30 2019-11-26 Elacestrant in combination with abemaciclib in women with breast cancer

Publications (2)

Publication Number Publication Date
AU2019388900A1 AU2019388900A1 (en) 2021-06-10
AU2019388900B2 true AU2019388900B2 (en) 2025-09-04

Family

ID=68966023

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019388900A Active AU2019388900B2 (en) 2018-11-30 2019-11-26 Elacestrant in combination with abemaciclib in women with breast cancer

Country Status (18)

Country Link
US (3) US20220117963A1 (https=)
EP (1) EP3886826A1 (https=)
JP (2) JP2022509262A (https=)
KR (1) KR20210097170A (https=)
CN (1) CN113164415A (https=)
AU (1) AU2019388900B2 (https=)
BR (1) BR112021010169A2 (https=)
CA (1) CA3120368A1 (https=)
EA (1) EA202191165A1 (https=)
IL (1) IL283502A (https=)
JO (1) JOP20210125A1 (https=)
MA (1) MA54293A (https=)
MX (1) MX2021005876A (https=)
MY (1) MY209833A (https=)
PH (1) PH12021551235A1 (https=)
SG (1) SG11202105455RA (https=)
UA (1) UA129403C2 (https=)
WO (1) WO2020112765A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021003440A2 (pt) 2018-09-07 2021-05-18 Sanofi sais de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil) pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxilato de metila e seu processo de preparação
EP4037768B1 (en) 2019-10-01 2023-10-11 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
AU2020399168A1 (en) 2019-12-09 2022-07-28 Sanofi Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
TW202233572A (zh) 2020-10-19 2022-09-01 法商賽諾菲公司 新穎之經取代的6,7-二氫-5h-苯並[7]輪烯衍生物，其製備方法及其治療用途
WO2022084280A1 (en) 2020-10-19 2022-04-28 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
WO2022106711A1 (en) * 2020-11-23 2022-05-27 Sanofi Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN114146182A (zh) * 2021-11-12 2022-03-08 深圳大学 Cdk4/6抑制剂与铂类化疗药物在制备治疗肿瘤的药物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018017410A1 (en) * 2016-07-22 2018-01-25 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer
US20180169101A1 (en) * 2015-04-29 2018-06-21 Radius Pharmaceuticals, Inc. Methods for treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017235450A1 (en) * 2016-03-15 2018-08-16 Merrimack Pharmaceuticals, Inc. Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180169101A1 (en) * 2015-04-29 2018-06-21 Radius Pharmaceuticals, Inc. Methods for treating cancer
WO2018017410A1 (en) * 2016-07-22 2018-01-25 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Goetz et al. J Clin Oncol. 2017 Nov 10;35(32):3638-3646 (Year: 2017) *
PANCHOLI ET AL: "Abstract 4160:", EXPERIMENTAL AND MOLECULAR THERAPEUTICS, 1 July 2017 (2017-07-01), XP055669846, Retrieved from the Internet *
Pernas S, Tolaney SM, Winer EP, Goel S. CDK4/6 inhibition in breast cancer: current practice and future directions. Ther Adv Med Oncol. 2018 Jul 17;10 (Year: 2018) *

Also Published As

Publication number Publication date
JOP20210125A1 (ar) 2019-11-26
EP3886826A1 (en) 2021-10-06
WO2020112765A1 (en) 2020-06-04
MA54293A (fr) 2021-10-06
BR112021010169A2 (pt) 2021-08-17
MY209833A (en) 2025-08-07
JP2025094216A (ja) 2025-06-24
CN113164415A (zh) 2021-07-23
SG11202105455RA (en) 2021-06-29
KR20210097170A (ko) 2021-08-06
PH12021551235A1 (en) 2021-12-13
US20260014153A1 (en) 2026-01-15
EA202191165A1 (ru) 2021-09-21
CA3120368A1 (en) 2020-06-04
US20250268899A1 (en) 2025-08-28
AU2019388900A1 (en) 2021-06-10
JP2022509262A (ja) 2022-01-20
IL283502A (en) 2021-07-29
US20220117963A1 (en) 2022-04-21
MX2021005876A (es) 2021-07-16
UA129403C2 (uk) 2025-04-16

Similar Documents

Publication Publication Date Title
AU2019388900B2 (en) Elacestrant in combination with abemaciclib in women with breast cancer
US20250367141A1 (en) Methods for treating cancer
RU2841076C2 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
AU2019392908B2 (en) Methods for treating cancer in models harboring ESR1 mutations
HK40079056A (en) Methods of treating cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)